Brainomix 360 e-Lung | Interstitial Lung Disease (ILD)

Brainomix 360 e-Lung: Vision to Precision

Brainomix e-Lung is an FDA-cleared, AI-powered imaging software platform that automatically identifies and quantifies features on CT lung scans enabling clinicians to more easily identify changes including subtle deteriorations over multiple scan timepoints.

Powered by novel, proprietary technology, e-Lung has been clinically validated to quantify lung features associated with Interstitial Lung Disease (ILD).

Patients with ILD can develop Progressive Pulmonary Fibrosis (PPF), which causes irreversible lung damage and leads to early mortality. The key to the best outcome and survival for patients is early initiation of treatment. However, identifying patients eligible for treatment based on imaging can be challenging, even for experts.

Enabling Earlier Detection of PPF, New Studies Show

Results from REVISE PPF - a retrospective research study conducted with the University of Chicago, Weill Cornell Medical, and the University of Alabama at Birmingham - have been presented at the European Respiratory Society (ERS) Congress and the CHEST Annual Meeting in 2025, showing:

e-Lung could have supported an earlier diagnosis of PPF in 62% of patients and up to 21 months earlier.
e-Lung identified CT progression in 77% of patients deemed clinically stable.
e-Lung accurately identified patients at risk of developing future PPF from a single baseline scan.
e-Lung metrics on the first patient scan are robust, independent predictors of mortality.

Transforming Pulmonary Fibrosis Care

“AI-powered CT analysis has the potential to transform pulmonary fibrosis care. It can enhance early detection, precisely quantify disease, and track progression over time.

"The data we have shown for e-Lung is very promising, and the ability to objectively assess parenchymal changes to predict disease trajectory and treatment responses could really help us personalize treatment decisions and improve outcomes for patients living with pulmonary fibrosis," said Dr Teja Kulkarni, Associate Professor and Director of the ILD Program at the University of Alabama at Birmingham.

Validated by the INBUILD Trial

Through a research collaboration and partnership with Boehringer Ingelheim, the global leader in pulmonary fibrosis therapies, Brainomix were granted privileged access to the landmark INBUILD clinical trial dataset to run the first quantitative CT analysis.

The results demonstrate e-Lung quantitative CT measurements can accurately and sensitively facilitate identification of PPF, and establish the value of e-Lung quantitative metrics as a prognostic tool for the assessment of PPF progression.

“The technology [e-Lung] may help in monitoring disease progression and tailoring treatment plans to patients individually. This will ultimately improve outcomes and quality of life for those affected,” Martin Beck, Therapeutic Area Head for Inflammation, Boehringer Ingelheim.

Click here to read more of Martin's interview.

Studies have explored a novel configuration of density and volume parameters, the Weighted Reticular Vascular Score (WRVS), which characterizes the total extent of peripheral fibrosis.

WRVS is a strong predictor of FVC decline in IPF patients.

(Devaraj A, AJRCCM May 2024)

An increase in WRVS is linked to greater risk of mortality.

(George PM, ERJ Open Res Dec 2024)

A change in WRVS of 3% was a more accurate predictor of mortality compared with FVC decline or radiologically-defined progression.

(George PM, ERJ Open Res Dec 2024)

Hear from our valued partners and collaborators

TIPAL Study

Norwich, UK

"It is great to have the chance to incorporate the cutting-edge CT scanning technology, e-Lung, developed by Brainomix into the TIPAL study."

Elizabeth Estes

OSIC Executive Director

"Brainomix's history of establishing successful collaborations, and their expertise in AI imaging biomarkers, certainly brings positive momentum to OSIC."

Bridge Biotherapeutics

Seoul, South Korea

“We believe that the partnership with Brainomix will enable us to generate supplemental efficacy data from our clinical study on IPF patients based on their combined imaging technology and expertise. We expect to gain further insights, including earlier prediction of treatment response in patients.”

OSIC

Chicago, USA

“We are pleased to see these encouraging data and developments from Brainomix as they highlight the important value of our consortium in enabling the development of novel solutions to combat Pulmonary Fibrosis.”